These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1010 related articles for article (PubMed ID: 28315051)
1. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes. Gu J; Al-Bayati K; Ho EA Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051 [TBL] [Abstract][Full Text] [Related]
2. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy. Li TS; Yawata T; Honke K Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005 [TBL] [Abstract][Full Text] [Related]
3. Targeted siRNA delivery by anti-HER2 antibody-modified nanoparticles of mPEG-chitosan diblock copolymer. Wang Y; Liu P; Du J; Sun Y; Li F; Duan Y J Biomater Sci Polym Ed; 2013; 24(10):1219-32. PubMed ID: 23713424 [TBL] [Abstract][Full Text] [Related]
4. T cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles. Lee J; Yun KS; Choi CS; Shin SH; Ban HS; Rhim T; Lee SK; Lee KY Bioconjug Chem; 2012 Jun; 23(6):1174-80. PubMed ID: 22607555 [TBL] [Abstract][Full Text] [Related]
5. Stability, Intracellular Delivery, and Release of siRNA from Chitosan Nanoparticles Using Different Cross-Linkers. Raja MA; Katas H; Jing Wen T PLoS One; 2015; 10(6):e0128963. PubMed ID: 26068222 [TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effects in mice induced by survivin-targeted siRNA delivered through polysaccharide nanoparticles. Yang F; Huang W; Li Y; Liu S; Jin M; Wang Y; Jia L; Gao Z Biomaterials; 2013 Jul; 34(22):5689-99. PubMed ID: 23632321 [TBL] [Abstract][Full Text] [Related]
7. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells. Jafari R; Majidi Zolbanin N; Majidi J; Atyabi F; Yousefi M; Jadidi-Niaragh F; Aghebati-Maleki L; Shanehbandi D; Soltani Zangbar MS; Rafatpanah H Iran Biomed J; 2019 Jan; 23(1):21-33. PubMed ID: 30041514 [TBL] [Abstract][Full Text] [Related]
8. Inhibiting influenza virus replication and inducing protection against lethal influenza virus challenge through chitosan nanoparticles loaded by siRNA. Jamali A; Mottaghitalab F; Abdoli A; Dinarvand M; Esmailie A; Kheiri MT; Atyabi F Drug Deliv Transl Res; 2018 Feb; 8(1):12-20. PubMed ID: 29063498 [TBL] [Abstract][Full Text] [Related]
9. Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core. Clark AJ; Davis ME Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12486-91. PubMed ID: 26392563 [TBL] [Abstract][Full Text] [Related]
10. Carbosilane dendrimers to transfect human astrocytes with small interfering RNA targeting human immunodeficiency virus. Jiménez JL; Clemente MI; Weber ND; Sanchez J; Ortega P; de la Mata FJ; Gómez R; García D; López-Fernández LA; Muñoz-Fernández MA BioDrugs; 2010 Oct; 24(5):331-43. PubMed ID: 20795754 [TBL] [Abstract][Full Text] [Related]
11. PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting. Monsalve Y; Tosi G; Ruozi B; Belletti D; Vilella A; Zoli M; Vandelli MA; Forni F; López BL; Sierra L Nanomedicine (Lond); 2015; 10(11):1735-50. PubMed ID: 26080696 [TBL] [Abstract][Full Text] [Related]
12. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency. Ragelle H; Riva R; Vandermeulen G; Naeye B; Pourcelle V; Le Duff CS; D'Haese C; Nysten B; Braeckmans K; De Smedt SC; Jérôme C; Préat V J Control Release; 2014 Feb; 176():54-63. PubMed ID: 24389132 [TBL] [Abstract][Full Text] [Related]
13. Galactosylated trimethyl chitosan-cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages. Zhang J; Tang C; Yin C Biomaterials; 2013 May; 34(14):3667-77. PubMed ID: 23419643 [TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106 [TBL] [Abstract][Full Text] [Related]
16. Optimization of chitosan nanoparticles as an anti-HIV siRNA delivery vehicle. Iranpur Mobarakeh V; Modarressi MH; Rahimi P; Bolhassani A; Arefian E; Atyabi F; Vahabpour R Int J Biol Macromol; 2019 May; 129():305-315. PubMed ID: 30738164 [TBL] [Abstract][Full Text] [Related]
17. Brain pharmacokinetics of neurotoxin-loaded PLA nanoparticles modified with chitosan after intranasal administration in awake rats. Zhang X; Liu L; Chai G; Zhang X; Li F Drug Dev Ind Pharm; 2013 Nov; 39(11):1618-24. PubMed ID: 24087853 [TBL] [Abstract][Full Text] [Related]
18. Co-delivery of hypoxia inducible factor-1α small interfering RNA and 5-fluorouracil to overcome drug resistance in gastric cancer SGC-7901 cells. Chen Y; Sun L; Guo D; Wu Z; Chen W J Gene Med; 2017 Dec; 19(12):. PubMed ID: 29106062 [TBL] [Abstract][Full Text] [Related]
19. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis. Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789 [TBL] [Abstract][Full Text] [Related]
20. Delivery of siRNA targeting tumor metabolism using non-covalent PEGylated chitosan nanoparticles: Identification of an optimal combination of ligand structure, linker and grafting method. Corbet C; Ragelle H; Pourcelle V; Vanvarenberg K; Marchand-Brynaert J; Préat V; Feron O J Control Release; 2016 Feb; 223():53-63. PubMed ID: 26699426 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]